Novel algorithm on wearable devices can detect irregular heartbeat, may prompt early care

Research Highlights:

  • A novel software algorithm developed for wearable devices, such as smartwatches and fitness trackers, was able to detect irregular heart rhythms.
  • Analysis of heartbeat data for nearly half a million wearable-device users found that the algorithm was able to accurately detect irregular heart rhythms, indicating possible atrial fibrillation.
  • This feature may help identify individuals with undiagnosed atrial fibrillation and aid in early intervention and improved outcomes.

Embargoed until 2:02 p.m./3:02 p.m. ET, Sunday, Nov. 14, 2021

DALLAS, Nov. 14, 2021 — A novel software algorithm compatible with a wide range of smartwatches and fitness trackers detected irregular heart rhythms and accurately identified undiagnosed atrial fibrillation 98% of the time, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2021. The meeting is fully virtual, Saturday, November 13-Monday, November 15, 2021, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide.

Many smartwatches and fitness trackers can detect the wearer’s pulse rate using light sensors. Researchers developed a novel software algorithm to analyze pulse rate signals and infer the presence of atrial fibrillation (AFib) on one brand of wearables. The algorithm operates during periods of inactivity and uses a process that examines continuous and overlapping episodes of pulse information from the wearable device to analyze for an irregular heart rhythm. The algorithm requires at least 30 minutes of sensing irregular heart rhythms to indicate the presence of possible atrial fibrillation.

“Undiagnosed atrial fibrillation can lead to strokes, and early detection of atrial fibrillation may allow doctors to prescribe medications that are effective at preventing strokes,” said Steven A. Lubitz, M.D., M.P.H., associate professor of medicine at Harvard Medical School and cardiologist at the Massachusetts General Hospital in Boston.

In this study, conducted from May through October 2020, investigators from Massachusetts General Hospital and fitness wearable manufacturer Fitbit® remotely enrolled more than 455,000 adult smartwatch or fitness tracker users in the U.S. None of the study participants had a self-reported prior diagnosis of atrial fibrillation. The average age of the participants was 47 years; 71% were female; and 73% were white. The data from their devices were analyzed using the novel software algorithm.

Participants who had an irregular heart rhythm detected by the software algorithm were notified and invited to schedule a visit with a telehealth professional. After meeting with the telehealth doctor, participants received a one-week electrocardiogram (ECG) patch monitor to wear along with the smartwatch or fitness tracker.

The analysis found that the novel software algorithm was able to successfully detect atrial fibrillation, and the findings were consistent across age groups. Specifically:

  • Irregular heart rhythm detection occurred in 1% of individuals overall and 4% of adults older than 65 years.
  • Among individuals who received notification of an irregular heart rhythm, 32% had atrial fibrillation detected on a subsequent ECG patch monitor.
  • The ECG patch confirmed atrial fibrillation in 98% of individuals who had another irregular heart rhythm detection while wearing the ECG patch monitor.
  • For participants over 65 years old, a subgroup at elevated risk for stroke caused by atrial fibrillation, the algorithm corresponded to concurrent AFib 97% of the time.

“These results show that wearables have the ability to identify undiagnosed atrial fibrillation with high reliability,” Lubitz said. “Since so many consumers use wearables, it is possible that algorithms such as the one we studied could be applied widely to help identify undiagnosed atrial fibrillation, allowing patients to obtain care before devastating complications such as a disabling stroke may occur.”

He added, “Most of the episodes of undiagnosed atrial fibrillation detected occurred during sleep, and we suspect that these episodes were asymptomatic. Since the algorithm is most active when wearers are physically inactive, the wearable should be worn during sleep for the greatest benefits.”

The algorithm is currently being reviewed by the FDA for clearance and widespread use. The study did not test whether screening for atrial fibrillation leads to a reduction in strokes, which Lubitz notes is an opportunity for future research.

Co-authors are Anthony Faranesh, B.S.; Caitlin Selvaggi; Steven Atlas, M.D.; David D. McManus, M.D.; Daniel E. Singer, M.D.; Sherry Pagoto, Ph.D.; Alexandros Pantelopoulos, Ph.D. and Andrea Foulkes, Sc.D. Authors’ disclosures are listed in the abstract.

The study was funded by Fitbit.

Additional Resources:

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.

The American Heart Association’s Scientific Sessions 2021 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care professionals worldwide. The 3-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates in a fully virtual experience Saturday, November 13 through Monday, November 15, 2021. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2021 on social media via #AHA21.

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.orgFacebookTwitter or by calling 1-800-AHA-USA1.   


For Media Inquiries and AHA Expert Perspective:

AHA Communications & Media Relations in Dallas: 214-706-1173;

Bridgette McNeill:

For Public Inquiries: 1-800-AHA-USA1 (242-8721) and


AHA Logo
This link is provided for convenience only and is not an endorsement of either the linked-to entity or any product or service.